Since HIV-1 gp120 plays an important role in protective immune responses, the aim of this work is to potentiate the immunogenicity of this antigen through the generation of a novel MVA-based vaccine candidate against HIV/AIDS, containing the optimized stronger VACV LEO160 promoter controlling the expression of HIV-1 gp120 antigen. Here, ITIH4 is linked to AIDS.